- Home
- ALUR
as 02-21-2025 4:00pm EST
Stocks
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NATICK |
| Market Cap: | 24.7M | IPO Year: | N/A |
| Target Price: | $50.00 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.37 - $98.75 | Next Earning Date: | 03-20-2025 |
| Revenue: | $34,754,000 | Revenue Growth: | -46.05% |
| Revenue Growth (this year): | -37.8% | Revenue Growth (next year): | -1.34% |
Latest Allurion Technologies Inc. News
ALUR Breaking Stock News: Dive into ALUR Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Business Wire
3 days ago
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Business Wire
4 days ago
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Business Wire
9 days ago
Allurion Relaunches in France
Zacks
12 days ago
How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%
Investor's Business Daily
a month ago
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
GuruFocus.com
a month ago
Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement
Business Wire
a month ago
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
Compare ALUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALUR Allurion Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.